TY - JOUR
T1 - Management of ErbB2-positive breast cancer
T2 - Insights from preclinical and clinical studies with lapatinib
AU - Vogel, Charles
AU - Chan, Arlene
AU - Gril, Brunilde
AU - Kim, Sung Bae
AU - Kurebayashi, Junichi
AU - Liu, Li
AU - Lu, Yen Shen
AU - Moon, Hanlim
N1 - Funding Information:
Arlene Chan has received payments as an advisory board member from Roche and for speaking from Roche and GlaxoSmithKline; Junichi Kurebayashi has received payments for speaking from GlaxoSmithKline; Brunilde Gril has received grant support from the US Department of Defense Breast Cancer Research Program; Li Liu is an employee of and has shares in GlaxoSmithKline; Yen-Shen Lu has received grant support and payments for speaking from GlaxoSmithKline; Hanlim Moon is an employee of and has shares in GlaxoSmithKline; Charles Vogel has received grant support and payments for consulting and speaking from Genentech and grant support and payments for consulting, speaking and participation as a clinical trial investigator and advisory board member from GlaxoSmithKline.
Funding Information:
To enhance reader access to this peer-reviewed article, the authors opted for an open access publication. The open access and color printing publication charges for this article were funded by GlaxoSmithKline Asia Pacific.
PY - 2010/11
Y1 - 2010/11
N2 - The management of human epidermal growth factor receptor 2-positive (ErbB2+) breast cancer is challenging; patients with ErbB2+ breast tumors have more aggressive disease and a poor prognosis. The increasing incidence of breast cancer in Asia and the limitations of existing treatments pose additional challenges. In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer. These issues are: (i) trastuzumab therapy failure, (ii) development of central nervous system metastases, (iii) minimizing toxicity and (iv) selecting the most appropriate partners (chemotherapy and non-chemotherapy) for combination therapy with lapatinib. Lapatinib, in combination with chemotherapeutic agents, such as capecitabine, provides clinical benefits to patients with ErbB2+ breast cancer, including patients who develop progressive disease on trastuzumab. Lapatinib, in combination with non-chemotherapeutic agents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/ErbB2+ metastatic breast cancer. Encouraging results have also emerged regarding the synergistic effects of lapatinib in combination with other agents for the treatment of ErbB2+ breast cancer. Promising findings have also been reported for the use of lapatinib to prevent and treat central nervous system metastases. Collectively, these results indicate that the judicious use of lapatinib, an effective oral therapy with a manageable toxicity profile, can enhance the management of patients with ErbB2+ breast cancer.
AB - The management of human epidermal growth factor receptor 2-positive (ErbB2+) breast cancer is challenging; patients with ErbB2+ breast tumors have more aggressive disease and a poor prognosis. The increasing incidence of breast cancer in Asia and the limitations of existing treatments pose additional challenges. In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer. These issues are: (i) trastuzumab therapy failure, (ii) development of central nervous system metastases, (iii) minimizing toxicity and (iv) selecting the most appropriate partners (chemotherapy and non-chemotherapy) for combination therapy with lapatinib. Lapatinib, in combination with chemotherapeutic agents, such as capecitabine, provides clinical benefits to patients with ErbB2+ breast cancer, including patients who develop progressive disease on trastuzumab. Lapatinib, in combination with non-chemotherapeutic agents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/ErbB2+ metastatic breast cancer. Encouraging results have also emerged regarding the synergistic effects of lapatinib in combination with other agents for the treatment of ErbB2+ breast cancer. Promising findings have also been reported for the use of lapatinib to prevent and treat central nervous system metastases. Collectively, these results indicate that the judicious use of lapatinib, an effective oral therapy with a manageable toxicity profile, can enhance the management of patients with ErbB2+ breast cancer.
KW - Breast cancer
KW - ErbB1
KW - ErbB2
KW - Lapatinib
KW - Review
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=78049420759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049420759&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyq084
DO - 10.1093/jjco/hyq084
M3 - Review article
C2 - 20542996
AN - SCOPUS:78049420759
VL - 40
SP - 999
EP - 1013
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 11
M1 - hyq084
ER -